\
&
Contact us
28digital is the new name of EIT Digital since 2025. This is however not just a rebranding exercise but also signifies a moderate shift in their approach. It will from now on be centered around 3 keywords:
If you want to know more about their guidance, training, financing, etc. or if you want to become a partner, please have a look at their website. if you want to know more about their open and upcoming calls you can click here.
background information: The European Commission finances each knowledge and innovation community (KIC) of the EIT for a period a maximum 15 years. Afterwards it needs to finance itself through the benefits of its investments and other sources of funding. EIT digital reached this milestone in 2025 and to mark this transition, they decided to rename themselve. The name 28DIGITAL draws inspiration from this idea of a ‘28th regime’ (alternative to the regime/rules of the 27 member states). It is meant to be a truly European framework where digital innovation, talent and entrepreneurship can thrive across the Single Market. The number 28 also symbolises perfection in mathematics, as it is equal to the sum of its divisors (1 + 2 + 4 + 7 + 14 = 28) – a concept rooted in number theory, the foundation of cryptography, quantum algorithms, and supercomputing benchmarks.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
pascal.verheye@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.